Challenges in neuroprotective nanomedicine development: Progress towards noninvasive gene therapy of glaucoma

Nanomedicine

Volumn 7, Issue 7, 2012, Pages 1067-1083

  Alqawlaq, Samih ^a   Huzil, J Torin ^a   Ivanova, Marina V ^a   Foldvari, Marianna ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

extracellular barriers; glaucoma; intracellular barriers; neuroprotection; nonviral gene delivery

Indexed keywords

GLATIRAMER; IMMUNOLIPOSOME; MACROGOL; MELATONIN; RETINOIC ACID;

BLOOD EYE BARRIER; CELL MIGRATION; CROSS-SECTIONAL STUDY; DRUG PENETRATION; EYE PROTECTION; GENE TARGETING; GENE THERAPY; GLAUCOMA; HUMAN; INTERNALIZATION; INTRAOCULAR PRESSURE; NANOMEDICINE; NERVE CELL; NERVE FIBER TRANSPORT; NEUROPROTECTION; NON INVASIVE PROCEDURE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; TRABECULECTOMY; TRABECULOPLASTY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; EYE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLAUCOMA; HUMANS;

EID: 84864418999     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.69     Document Type: Review

References (125)

1. Margalit E, Sadda SR. Retinal and optic nerve diseases. Artif. Organs 27(11), 963-974 (2003). (Pubitemid 37414235)
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90(3), 262-267 (2006). (Pubitemid 43325451)
3. Foster A, Resnikoff S. The impact of vision 2020 on global blindness. Eye 19(10), 1133-1135 (2005). (Pubitemid 41823774)
4. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest. Ophthalmol. Vis. Sci. 38(1), 83-91 (1997). (Pubitemid 27051527)
5. Kass MA, Becker B. Genetics of primary open-angle glaucoma. Sight Sav. Rev. 48(1), 21-28 (1978). (Pubitemid 8346378)
6. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36(5), 774-786 (1995).
7. Iwabe S, Moreno-Mendoza NA, Trigo-Tavera F, Crowder C, Garcia-Sanchez GA. Retrograde axonal transport obstruction of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the retina and optic nerve of American Cocker Spaniel dogs with spontaneous glaucoma. Vet. Ophthalmol. 10(Suppl. 1), 12-19 (2007). (Pubitemid 350007140)
8. Quigley HA, Mckinnon SJ, Zack DJ et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest. Ophthalmol. Vis. Sci. 41(11), 3460-3466 (2000).
9. Flammer J, Orgul S, Costa VP et al. The impact of ocular blood fow in glaucoma. Prog. Retin. Eye Res. 21(4), 359-393 (2002). (Pubitemid 34879080)
10. Bonne C, Muller A, Villain M. Free radicals in retinal ischemia. Gen. Pharmacol. 30(3), 275-280 (1998). (Pubitemid 28046495)
11. Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp. Eye Res. 93(2), 196-203 (2010).
12. Liu Q, Ju WK, Crowston JG et al. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest. Ophthalmol. Vis. Sci. 48(10), 4580-4589 (2007). (Pubitemid 351260975)
13. Martin KR, Levkovitch-Verbin H, Valenta D, Baumrind L, Pease ME, Quigley HA. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest. Ophthalmol. Vis. Sci. 43(7), 2236-2243 (2002). (Pubitemid 34700653)
14. Morgan JE. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye (Lond.) 14(Pt 3B), 437-444 (2000). (Pubitemid 30479745)
15. Taylor S, Srinivasan B, Wordinger RJ, Roque RS. Glutamate stimulates neurotrophin expression in cultured Muller cells. Brain Res. Mol. Brain Res. 111(1-2), 189-197 (2003). (Pubitemid 36332343)
16. Johnson EC, Jia L, Cepurna WO, Doser TA, Morrison JC. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 48(7), 3161-3177 (2007). (Pubitemid 351261161)
17. Van Der Valk R, Webers CaB, Schouten JSaG, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112(7), 1177-1185 (2005). (Pubitemid 40916921)
18. Ang GS, Goh Y W, Azuara-Blanco A. Recurrent vitreous occlusion of glaucoma drainage device tube in a patient with glaucoma in aphakia: a case report. Cases J. 3, 55 (2010).
19. Bessero AC, Clarke PG. Neuroprotection for optic nerve disorders. Curr. Opin. Neurol. 23(1), 10-15 (2010).
20. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma-is there a future role? Exp. Eye Res. 91(5), 554-566 (2010).
21. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, Rosenstein RE. Melatonin in the eye: implications for glaucoma. Exp. Eye Res. 84(6), 1021-1030 (2007). (Pubitemid 46783812)
22. Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol. Med. 8(7), 319-323 (2002). (Pubitemid 34733384)
23. Guo L, Duggan J, Cordeiro MF. Alzheimer's disease and retinal neurodegeneration. Curr. Alzheimer Res. 7(1), 3-14 (2010).
24. Guo L, Salt TE, Luong V et al. Targeting amyloid-b in glaucoma treatment. Proc. Natl Acad. Sci. USA 104(33), 13444-13449 (2007).
25. Normando EM, Coxon KM, Guo L, Cordeiro MF. Focus on: amyloid b. Exp. Eye Res. 89(4), 446-447 (2009).
26. Nishikiori N, Osanai M, Chiba H et al. Experimental effect of retinoic acids on apoptosis during the development of diabetic retinopathy. Clin. Ophthalmol. 2(1), 233-235 (2008).
27. Sakamoto K, Hiraiwa M, Saito M et al. Protective effect of all-trans retinoic acid on NMDA-induced neuronal cell death in rat retina. Eur. J. Pharmacol. 635(1-3), 56-61 (2010).
28. Ellis-Behnke RG, Liang YX, You SW et al. Nano neuro knitting: peptide nanofber scaffold for brain repair and axon regeneration with functional return of vision. Proc. Natl Acad. Sci. USA 103(13), 5054-5059 (2006).
29. Harvey AR, Hu Y, Leaver SG et al. Gene therapy and transplantation in CNS repair: the visual system. Prog. Retin. Eye Res. 25(5), 449-489 (2006). (Pubitemid 44389960)
30. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr. Opin. Ophthalmol. 22(2), 78-86 (2011).
31. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med. Sci. Monit. 11(4), RA110-RA121 (2005). (Pubitemid 40546958)
32. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 6(4), 299-310 (2005). (Pubitemid 40469049)
33. Huang L, Hung MC, Wagner E. Non-viral vectors for gene therapy. Elsevier Academic Press, London, UK. 1 (2005).
34. Ward CM, Read ML, Seymour LW Systemic circulation of poly (L-lysine)/DNA vectors is infuenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood 97(8), 2221-2229 (2001). (Pubitemid 32291466)
35. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Natl Acad. Sci. USA 95(7), 3978-3983 (1998).
36. Van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum. Gene. Ther 14(2), 103-115 (2003). (Pubitemid 36418815)
37. Ishikawa H, Takano M, Matsumoto N et al. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene. Ther. 12(4), 289-298 (2005). (Pubitemid 40310131)
38. Leaver SG, Cui Q, Bernard O, Harvey AR. Cooperative effects of bcl-2 and AAV-mediated expression of CNTF on retinal ganglion cell survival and axonal regeneration in adult transgenic mice. Eur. J. Neurosci. 24(12), 3323-3332 (2006). (Pubitemid 44952599)
39. Weber AJ, Viswanathan S, Ramanathan C, Harman CD. Combined application of BDNF to the eye and brain enhances ganglion cell survival and function in the cat after optic nerve injury. Invest. Ophthalmol. Vis. Sci. 51(1), 327-334 (2010).
40. Benowitz L, Yin Y. Rewiring the injured CNS: lessons from the optic nerve. Exp. Neurol. 209(2), 389-398 (2008). (Pubitemid 351174128)
41. Benowitz LI, Yin Y. Optic nerve regeneration. Arch. Ophthalmol. 128(8), 1059-1064 (2010).
42. Barbe MF, Tytell M, Gower DJ, Welch WJ. Hyperthermia protects against light damage in the rat retina. Science 241(4874), 1817-1820 (1988).
43. Caprioli J, Kitano S, Morgan JE. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest. Ophthalmol. Vis. Sci. 37(12), 2376-2381 (1996). (Pubitemid 26391275)
44. Jeun M, Jeoung JW, Moon S et al. Engineered superparamagnetic Mn0.5Zn0.5Fe2O4 nanoparticles as a heat shock protein induction agent for ocular neuroprotection in glaucoma. Biomaterials 32(2), 387-394 (2011).
45. Malik JM, Shevtsova Z, Bahr M, Kugler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol. Ther. 11(3), 373-381 (2005). (Pubitemid 40277313)
46. Mckinnon SJ, Lehman DM, Tahzib NG et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol. Ther. 5(6), 780-787 (2002). (Pubitemid 34619071)
47. Kurz D, Ciulla TA. Novel approaches for retinal drug delivery Ophthalmol. Clin. N Am. 15(3), 405-410 (2002). (Pubitemid 35244818)
48. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Organ-specifc gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9, 465-472 (2003). (Pubitemid 38097614)
49. Liaw J, Chang SF, Hsiao FC. In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. Gene. Ther. 8(13), 999-1004 (2001). (Pubitemid 32633376)
50. Tong YC, Chang SF, Liu CY, Kao WW, Huang CH, Liaw J. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specifc promoters. J. Gene. Med. 9(11), 956-966 (2007). (Pubitemid 350104410)
51. Masuda I, Matsuo T, Yasuda T, Matsuo N. Gene transfer with liposomes to the intraocular tissues by different routes of administration. Invest. Ophthalmol. Vis. Sci. 37(9), 1914-1920 (1996). (Pubitemid 26265044)
52. Matsuo T, Masuda I, Yasuda T, Matsuo N. Gene transfer to the retina of rat by liposome eye drops. Biochem. Biophys. Res. Commun. 219(3), 947-950 (1996). (Pubitemid 26106783)
53. Johnson LN, Cashman SM, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol. Ther. 16(1), 107-114 (2008).
54. Grove J, Durr M, Quint MP, Plazonnet B. The effect of vehicle viscosity on the ocular bioavailability of L-653,328. Int. J. Pharmaceut. 66(1-3), 23-28 (1990).
55. Chrai SS, Robinson Jr. Ocular evaluation of methylcellulose vehicle in albino rabbits. J. Pharmaceut. Sci. 63(8), 1218-1223 (1974).
56. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Chitosan and its role in ocular therapeutics. Mini. Rev. Med. Chem. 9(14), 1639-1647 (2009).
57. Ijichi H, Hida T, Fukuda M, Azuma N. Scanning and transmission electron microscopic studies of the ultrastructure of the corneal endothelium in developing human eye. Nihon Ganka Gakkai Zasshi 96(11), 1351-1356 (1992). (Pubitemid 23121491)
58. Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J. Drug Target 12(9-10), 623-633 (2004). (Pubitemid 40100710)
59. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 20(4), 576-583 (2003). (Pubitemid 36438900)
60. Ameri K, Wagner E. Receptor-targeted polyplexes. In: Gene Therapy. Therapeutic Mechanisms and Strategies. Smyth-Templeton N (Ed.). Marcel Dekker Inc., NY, USA (2005).
61. Kircheis R, Wightman L, Kursa M, Ostermann E, Wagner E. Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment. Gene Ther. 9(11), 731-735 (2002). (Pubitemid 34591476)
62. Deshpande MC, Davies MC, Garnett MC et al. The effect of poly(ethylene glycol) molecular architecture on cellular interaction and uptake of DNA complexes. J. Control. Release 97(1), 143-156 (2004). (Pubitemid 38624517)
63. Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt SC. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J. Control. Release 117(2), 256-266 (2007). (Pubitemid 46161877)
64. Sanders NN, Peeters L, Lentacker I, Demeester J, De Smedt SC. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J. Control. Release 122(3), 226-235 (2007). (Pubitemid 47404669)
65. Bill A. The blood-aqueous barrier. Trans. Ophthalmol. Soc. UK 105(Pt 2), 149-155 (1986). (Pubitemid 16083289)
66. Smith RS. Ultrastructural studies of the blood-aqueous barrier. I. Transport of an electron-dense tracer in the iris and ciliary body of the mouse. Am. J. Ophthalmol. 71(5), 1066-1077 (1971).
67. Cunha-Vaz JG. The blood-retinal barriers. Doc. Ophthalmol. 41(2), 287-327 (1976).
68. Joussemet B, Belbellaa B, Mendes-Madeira A et al. Neonatal systemic delivery of scAAV9 in rodents and large animals results in gene transfer to RPE cells in the retina. Exp. Eye Res. 93(4), 491-502 (2011).
69. Campbell M, Nguyen AT, Kiang AS et al. An experimental platform for systemic drug delivery to the retina. Proc. Natl Acad. Sci. USA 106(42), 17817-17822 (2009).
70. Templeton NS. Gene and cell therapy: therapeutic mechanisms and strategies. Marcel Dekker. CRC Press, FL, USA (2004).
71. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl Acad. Sci. USA 93(22), 12349-12354 (1996). (Pubitemid 26367146)
72. Provost N, Le Meur G, Weber M et al. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11(2), 275-283 (2005).
73. Llobet A, Gasull X, Gual A. Understanding trabecular meshwork physiology: a key to the control of intraocular pressure? News Physiol. Sci. 18, 205-209 (2003). (Pubitemid 37356868)
74. Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of 'plaque material' in the inner-and outer wall of Schlemm's canal in normal-and glaucomatous eyes. Exp. Eye Res. 42(5), 443-455 (1986). (Pubitemid 16121084)
75. Buller C, Johnson D. Segmental variability of the trabecular meshwork in normal and glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 35(11), 3841-3851 (1994). (Pubitemid 24334541)
76. Liu X, Hu Y, Filla MS et al. The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outfow facility in organ cultured monkey eyes. Mol. Vis. 11, 1112-1121 (2005). (Pubitemid 41819512)
77. Agarwal R, Agarwal P. Future target molecules in antiglaucoma therapy: tgf-b may have a role to play. Ophthalmic Res. 43(1), 1-10 (2010).
78. Welge-Lussen U, May CA, Lutjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-b1 and TGF-b2. Invest. Ophthalmol. Vis. Sci. 41(8), 2229-2238 (2000). (Pubitemid 30450997)
79. Howell GR, Libby RT, Jakobs TC et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J. Cell Biol. 179(7), 1523-1537 (2007).
80. Gauthier R, Joly S, Pernet V, Lachapelle P, Di Polo A. Brain-derived neurotrophic factor gene delivery to muller glia preserves structure and function of light-damaged photoreceptors. Invest. Ophthalmol. Vis. Sci. 46(9), 3383-3392 (2005). (Pubitemid 44264329)
81. Johnson EC, Morrison JC. Friend or foe? Resolving the impact of glial responses in glaucoma. J. Glaucoma 18(5), 341-353 (2009).
82. Sarthy V. Targeting müller cells for gene therapy. In: Retinal Degenerative Diseases and Experimental Therapy. Hollyfeld JG, Anderson RE, Lavail MM (Eds). Springer US, NY, USA, 293-302 (1999).
83. Garcia M, Forster V, Hicks D, Vecino E. Effects of muller glia on cell survival and neuritogenesis in adult porcine retina in vitro. Invest. Ophthalmol. Vis. Sci. 43(12), 3735-3743 (2002). (Pubitemid 35470613)
84. Kawasaki A, Otori Y, Barnstable CJ. Muller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest. Ophthalmol. Vis. Sci. 41(11), 3444-3450 (2000).
85. Wen R, Song Y, Cheng T et al. Injury-induced upregulation of bFGF and CNTF mRNAS in the rat retina. J. Neurosci. 15(11), 7377-7385 (1995).
86. Greenberg KP, Geller SF, Schaffer DV, Flannery JG. Targeted transgene expression in müller glia of normal and diseased retinas using lentiviral vectors. Invest. Ophthalmol. Vis. Sci. 48(4), 1844-1852 (2007). (Pubitemid 351261374)
87. Klimczak RR, Koerber JT, Dalkara D, Flannery JG, Schaffer DV. A novel adeno-associated viral variant for effcient and selective intravitreal transduction of rat Muller cells. PLoS One 4(10), E7467 (2009).
88. Lagali PS, Balya D, Awatramani GB et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat. Neurosci. 11(6), 667-675 (2008). (Pubitemid 351748114)
89. Bergen JM, Pun SH. Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons. J. Gene. Med. 10(2), 187-197 (2008). (Pubitemid 351267160)
90. Rejman J, Bragonzi A, Conese M. Role of clathrin-and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes. Mol. Ther. 12(3), 468-474 (2005). (Pubitemid 41150132)
91. Rejman J, Conese M, Hoekstra D. Gene transfer by means of lipo-and polyplexes: role of clathrin and caveolae-mediated endocytosis. J. Liposome Res. 16(3), 237-247 (2006). (Pubitemid 44358997)
92. Li E, Stupack D, Klemke R, Cheresh DA, Nemerow GR. Adenovirus endocytosis via a(v) integrins requires phosphoinositide-3-OH kinase. J. Virol. 72(3), 2055-2061 (1998). (Pubitemid 28100760)
93. Juliano RL, Ming X, Nakagawa O, Xu R, Yoo H. Integrin targeted delivery of gene therapeutics. Theranostics 1, 211-219 (2011).
94. Bergen JM, Pun SH. Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons. J. Gene. Med. 10(2), 187-197 (2008). (Pubitemid 351267160)
95. Daukas G, Zigmond SH. Inhibition of receptor-mediated but not fuid-phase endocytosis in polymorphonuclear leukocytes. J. Cell Biol. 101(5), 1673-1679 (1985). (Pubitemid 16192138)
96. Reynolds AJ, Bartlett SE, Hendry IA. Molecular mechanisms regulating the retrograde axonal transport of neurotrophins. Brain Res. Brain Res. Rev. 33(2-3), 169-178 (2000).
97. Goldstein AY, Wang X, Schwarz TL. Axonal transport and the delivery of pre-synaptic components. Curr. Opin. Neurobiol. 18(5), 495-503 (2008).
98. Murthy K, Bhat JM, Koushika SP. In vivo imaging of retrogradely transported synaptic vesicle proteins in Caenorhabditis elegans neurons. Traffc 12(1), 89-101 (2011).
99. Drake DM, Pack DW. Biochemical investigation of active intracellular transport of polymeric gene-delivery vectors. J. Pharm. Sci. 97(4), 1399-1413 (2008).
100. Moseley GW, Roth DM, Dejesus MA et al. Dynein light chain association sequences can facilitate nuclear protein import. Mol. Biol. Cell 18(8), 3204-3213 (2007). (Pubitemid 47235323)
101. Luby-Phelps K, Taylor DL, Lanni F. Probing the structure of cytoplasm. J. Cell Biol. 102(6), 2015-2022 (1986). (Pubitemid 16052141)
102. Zhou R, Geiger RC, Dean DA. Intracellular traffcking of nucleic acids. Expert Opin. Drug Deliv. 1(1), 127-140 (2004).
103. Minchin RF, Yang S. Endosomal disruptors in non-viral gene delivery. Expert Opin. Drug Deliv. 7(3), 331-339 (2010).
104. Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem. Soc. Trans. 35(Pt 1), 68-71 (2007).
105. Edinger D, Wagner E. Bioresponsive polymers for the delivery of therapeutic nucleic acids. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(1), 33-46 (2011).
106. Lechardeur D, Verkman A, Lukacs G. Intracellular routing of plasmid DNA during non-viral gene transfer. Adv. Drug Deliv. Rev. 57(5), 755-767 (2005). (Pubitemid 40332601)
107. Allen TD, Rutherford SA, Murray S, Drummond SP, Goldberg MW, Kiseleva E. Chapter 20 scanning electron microscopy of nuclear structure. In: Methods in Cell Biology, Terence DA (Ed.). Academic Press, MO, USA 389-409 (2008).
108. Dworetzky SI, Feldherr CM. Translocation of RNA-coated gold particles through the nuclear pores of oocytes. J. Cell Biol. 106(3), 575-584 (1988). (Pubitemid 18089958)
109. Paine PL, Moore LC, Horowitz SB. Nuclear envelope permeability. Nature 254(5496), 109-114 (1975).
110. Feldherr CM, Kallenbach E, Schultz N. Movement of a karyophilic protein through the nuclear pores of oocytes. J. Cell Biol. 99(6), 2216-2222 (1984). (Pubitemid 15181886)
111. Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: defnition, function, and interaction with importin a. J. Biol. Chem. 282(8), 5101-5105 (2007). (Pubitemid 47093710)
112. Chan CK, Jans DA. Using nuclear targeting signals to enhance non-viral gene transfer. Immunol. Cell Biol. 80(2), 119-130 (2002). (Pubitemid 34298084)
113. Fei Y, Hughes TE. Nuclear traffcking of photoreceptor protein crx: the targeting sequence and pathologic implications. Invest. Ophthalmol. Vis. Sci. 41(10), 2849-2856 (2000).
114. Haller JA, Bandello F, Belfort R Jr et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6), 1134-1146 E1133 (2010).
115. Weber AJ, Harman CD, Viswanathan S. Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J. Physiol. 586(Pt 18), 4393-4400 (2008).
116. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin. Drug Deliv. 5(5), 567-581 (2008). (Pubitemid 351877434)
117. de la Fuente M, Ravina M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 62(1), 100-117 (2010).
118. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58(11), 1131-1135 (2006).
119. Annick L. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 57(11), 1595-1639 (2005).
120. Taylor SL, Rahim A, Bush N, Bamber J, Porter C. Ultrasound-mediated microbubble destruction and retroviral gene delivery. Mol. Ther. 11(S1), S188-S188 (2005).
121. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275(3), 1625-1629 (2000). (Pubitemid 30060778)
122. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modifed for endosomal escape. Adv. Drug Deliv. Rev. 61(9), 704-709 (2009).
123. Bergen JM, Park IK, Horner PJ, Pun SH. Nonviral approaches for neuronal delivery of nucleic acids. Pharmaceut. Res. 25(5), 983-998 (2007).
124. Raju HB, Hu Y, Vedula A, Dubovy SR, Goldberg JL. Evaluation of magnetic micro-and nanoparticle toxicity to ocular tissues. PLoS One 6(5), E17452 (2011).
125. Viola F, Mapelli C, Galimberti D et al. Solid lipid nanoparticles topically administered in rabbits as new drug delivery system: a preliminary study of safety and bioavailability. Invest. Ophthalmol. Vis. Sci. 50(5), 2423 (2009).